1229236-84-3

Upstream product

• 1229236-79-6 (E)-N'-(6-chloropyridazin-3-yl)-N,N-dimethylacetimidamide 
• 1229236-80-9 (4-chloro-2-fluorophenyl)(6-chloro-2-methylimidazo-[1,2-b]pyridazin-3-yl)methanone 
• 175711-83-8 4’-chloro-2’-fluoroacetophenone 
• 299411-67-9 2-chloro-1-(4-chloro-2-fluorophenyl)ethan-1-one 
• 111-44-4 3-oxa-1,5-dichloropentane 
• 1229236-83-2 (4-chloro-2-fluorophenyl)(6-chloro-2-methyl-8-(morpholino-methyl)imidazo[1,2-b]pyridazin-3-yl)methanone 

Downstream Products

• 1229236-85-4 4-((6-chloro-3-(4-chloro-2-fluorobenzyl)-2-methylimidazo-[1,2-b]pyridazin-8-yl)methyl)morpholine 
• 1229236-88-7 4-((6-chloro-3-(4-chloro-2-fluorobenzyl)-2-methylimidazo-[1,2-b]pyridazin-8-yl)methyl)morpholine hydrochloride 
• 1440192-12-0 C₁₉H₂₀ClFN₄O 
• 1440192-09-5 C₁₉H₂₀ClFN₄O₂ 
• 1440192-10-8 C₁₅H₁₃ClFN₃O 

Relevant academic research and scientific papers

Development of a Stepwise Reductive Deoxygenation Process by Ru-Catalysed Homogeneous Ketone Reduction and Pd-Catalysed Hydrogenolysis in the Presence of Cu Salts

A stepwise catalytic reduction of ketone 1 to alcohol 2 and subsequently to aryl(imidazo[1,2-b]pyridazinyl)methane 3 is described, which provides synthetically useful chemoselectivity at acceptably low catalyst loadings. Undesired reactive sites include a

Development and a practical synthesis of the JAK2 inhibitor LY2784544

The route selection and process research and development of a practical synthesis for JAK2 inhibitor LY2784544 is described. The first-generation synthesis route, similar to that used in discovery for derivatization of a benzylic amine moiety, was 14 overall steps and possessed several steps that required extensive development for large-scale production. Route selection considerations led to a modified synthesis that utilized a novel vanadium-catalyzed carbon-carbon bond-forming arylation reaction for incorporation of the key benzylic morpholine moiety. A protecting group used to mask an amino pyrazole unit was modified from PMB to tert-butyl, resulting in a dramatic reduction in the overall length of the route. These two major changes resulted in an eight-step synthesis, which was six steps shorter than the first-generation synthesis. In the pilot plant, the new synthesis was scaled to produce >100 kg of LY2784544 in high yield and purity under GMP conditions. The overall development including the vanadium-catalyzed C-C bond-forming methodology, a ketone reductive deoxygenation, and a palladium-catalyzed amination is described.

AMINO PYRAZOLE COMPOUND

The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.